logo
Plus   Neg
Share
Email

Pfizer Reports Data From Clinical Trial For 20-Valent Pneumococcal Conjugate Vaccine

Pfizer Inc. (PFE) presented the full analysis from one of its phase 3 studies which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease. In the study, researchers found that all 20 vaccine serotypes induced robust responses across three age cohorts (60 years, 50-59 years, 18-49 years).

For the primary safety analysis, the frequency of adverse events among participants within 1 month after receiving 20vPnC was generally similar to participants receiving 13vPnC. Vaccine related adverse events for 20vPnC and 13vPnC respectively were, 60 years: 0.9% and 1.5%; 50-59 years: 0.9% and 0.9%; and 18-49 years: 1.5% and 1.8%. No serious adverse events were considered vaccine related.

The company had announced top-line data from the phase 3 study in March 2020. Earlier in the current month, Pfizer submitted the 20vPnC biologics license application for adults 18 years of age or older to the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT